Výsledky vyhledávání

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

Autor: Lori Capone, Loveland Ma, Cheung Yf, Lei Wu, Anita Gandhi, Peter H. Schafer, Justin B. Bartlett, Amos Gilhar, Mary Adams, George S. Baillie, D. I. Stirling, G. W. Muller, Anastasia Parton, Houslay, Man Hw

Publikováno v: British Journal of Pharmacology. 159:842-855

Background and purpose: Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other chronic inflammatory diseases. The inhibitory effects of apremilast on pro-inflammatory responses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b99b2bd538e86f4b148f758f94ec804b
https://doi.org/10.1111/j.1476-5381.2009.00559.x

Zobrazit plný text záznamu

ChemInform Abstract: Thalidomide: From Tragedy to New Drug Discovery

Autor: G. W. Muller

Publikováno v: ChemInform. 28

Analogues of thalidomide have the potential to treat a number of inflammatory and autoimmune diseases

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11297156fdde28b4c9bc7ac7c3040a70
https://doi.org/10.1002/chin.199716285

Zobrazit plný text záznamu

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

Autor: P H, Schafer, A, Parton, A K, Gandhi, L, Capone, M, Adams, L, Wu, J B, Bartlett, M A, Loveland, A, Gilhar, Y-F, Cheung, G S, Baillie, M D, Houslay, H-W, Man, G W, Muller, D I, Stirling

Publikováno v: British journal of pharmacology. 159(4)

Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other chronic inflammatory diseases. The inhibitory effects of apremilast on pro-inflammatory responses of human primary periph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3341fc207e2b60462624c8e47b819406
https://pubmed.ncbi.nlm.nih.gov/20050849

Zobrazit plný text záznamu

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

Autor: Keith Dredge, A Polychronis, A G Dalgleish, H Kristeleit, David I. Stirling, G W Muller, J B Bartlett, Jerome B. Zeldis, S Nicholson, Hardev Pandha, I A Clarke, Agnieszka Michael

Publikováno v: British Journal of Cancer

We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMID trade mark ), in the treatment of patients with metastatic malignant melanoma and other advanced cancers. A total of 20 heavily pretreated patients recei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9730fb37549b09120561e3a4b40b80f1
https://pubmed.ncbi.nlm.nih.gov/14997189

Zobrazit plný text záznamu

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

Autor: Chen R, David I. Stirling, Marriott Jb, Angus G. Dalgleish, G W Muller, Man Hw, Macdonald Cd, Keith Dredge

Publikováno v: British Journal of Cancer

The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning to enter trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653a3afaf21b5abbacf2c9616d2ae0ed
https://openaccess.sgul.ac.uk/id/eprint/718/1/87-6600607a.pdf

Zobrazit plný text záznamu

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

Autor: J B Marriott, I A Clarke, David I. Stirling, A G Dalgleish, G W Muller, Keith Dredge

Publikováno v: Clinical and experimental immunology. 130(1)

Thalidomide (Thd) is clinically useful in a number of conditions where its efficacy is probably related to its anti-TNF-alpha activity. More recently, Thd has also been shown to co-stimulate T cells and second generation co-stimulatory (IMiD trade ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45ade940e215d1a08dcee2a80842c71
https://pubmed.ncbi.nlm.nih.gov/12296856

Zobrazit plný text záznamu

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

Autor: J L, Prehn, C, Landers, G W, Muller, H W, Man, D I, Stirling, S R, Targan

Publikováno v: Journal of clinical immunology. 21(5)

In Crohn's disease, intestinal lamina propria (LP) T cells overproduce TNF-alpha and IFN-gamma, and clinical and animal studies indicate that this is pathogenic. Thalidomide influences cytokine production by leukocytes, inhibiting macrophage TNF-alph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b4d05491754bc0678f01d6b7f984683b
https://pubmed.ncbi.nlm.nih.gov/11720008

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání